JP2022508953A5 - - Google Patents
Info
- Publication number
- JP2022508953A5 JP2022508953A5 JP2021547054A JP2021547054A JP2022508953A5 JP 2022508953 A5 JP2022508953 A5 JP 2022508953A5 JP 2021547054 A JP2021547054 A JP 2021547054A JP 2021547054 A JP2021547054 A JP 2021547054A JP 2022508953 A5 JP2022508953 A5 JP 2022508953A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- compound according
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748906P | 2018-10-22 | 2018-10-22 | |
| US62/748,906 | 2018-10-22 | ||
| US201962858790P | 2019-06-07 | 2019-06-07 | |
| US62/858,790 | 2019-06-07 | ||
| PCT/US2019/057362 WO2020086533A1 (en) | 2018-10-22 | 2019-10-22 | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022508953A JP2022508953A (ja) | 2022-01-19 |
| JP2022508953A5 true JP2022508953A5 (enExample) | 2023-06-22 |
Family
ID=68610300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547054A Pending JP2022508953A (ja) | 2018-10-22 | 2019-10-22 | Ｈｂｖの処置のための５員のヘテロアリールカルボキサミド化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11560370B1 (enExample) |
| EP (1) | EP3870296A1 (enExample) |
| JP (1) | JP2022508953A (enExample) |
| KR (1) | KR20210095143A (enExample) |
| CN (1) | CN113195055A (enExample) |
| AU (1) | AU2019364352A1 (enExample) |
| BR (1) | BR112021007602A2 (enExample) |
| CA (1) | CA3117449A1 (enExample) |
| IL (1) | IL282433A (enExample) |
| MA (1) | MA53983A (enExample) |
| MX (1) | MX2021004580A (enExample) |
| PH (1) | PH12021550887A1 (enExample) |
| SG (1) | SG11202104086PA (enExample) |
| TW (1) | TW202028190A (enExample) |
| WO (1) | WO2020086533A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111205264A (zh) * | 2020-02-25 | 2020-05-29 | 成都睿智化学研究有限公司 | 一种合成同位羟基和甲磺酰甲基化合物的新方法 |
| WO2021216642A1 (en) * | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | Pyrazole carboxamide compounds for treatment of hbv |
| CN121248511A (zh) * | 2020-04-22 | 2026-01-02 | 组装生物科学股份有限公司 | 用于治疗hbv的5元杂芳基甲酰胺化合物 |
| EP4251622A1 (en) * | 2020-11-25 | 2023-10-04 | F. Hoffmann-La Roche AG | Aromatic bridged ring amide derivatives for the treatment and prophylaxis of hepatitis b virus infection |
| WO2023069547A1 (en) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| AU2022370483A1 (en) * | 2021-10-20 | 2024-05-02 | Assembly Biosciences, Inc. | Novel crystalline forms |
| WO2023105481A1 (en) * | 2021-12-10 | 2023-06-15 | Assembly Biosciences, Inc. | Pharmaceutical compositions for the treatment of hbv |
| WO2024173196A1 (en) * | 2023-02-17 | 2024-08-22 | Merck Sharp & Dohme Llc | Plasma kallikrein inhibitors |
| KR102827002B1 (ko) * | 2023-06-28 | 2025-06-30 | 국립순천대학교산학협력단 | 신규한 마리노바자난 화합물 및 이를 포함하는 암 전이 및 침윤 억제, 또는 암 치료용 조성물 |
| WO2025029961A1 (en) * | 2023-07-31 | 2025-02-06 | Makscientific, Llc | Pharmaceutical compositions, and preparation and methods of use thereof |
| CN117603089A (zh) * | 2023-11-29 | 2024-02-27 | 南通瑞合达医药科技有限公司 | 一种环戊腈的合成方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002342607B2 (en) * | 2001-08-06 | 2006-10-19 | Pharmacia Italia S.P.A. | Aminoisoxazole derivatives active as kinase inhibitors |
| GB0228417D0 (en) * | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
| CN101754961A (zh) | 2007-04-20 | 2010-06-23 | 先灵公司 | 嘧啶酮衍生物及其使用方法 |
| NZ596538A (en) * | 2009-05-12 | 2014-04-30 | Romark Lab Lc | Haloalkyl heteroaryl benzamide compounds |
| JP5977347B2 (ja) | 2011-07-01 | 2016-08-24 | バルーク エス．ブルームバーグ インスティテュート | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
| WO2013010069A1 (en) | 2011-07-13 | 2013-01-17 | Indiana University Research And Technology Corporation | Modified viral structural protein with antiviral activity |
| EP2800742B1 (en) | 2012-01-06 | 2016-04-06 | Janssen Sciences Ireland UC | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b |
| EA026957B1 (ru) | 2012-08-28 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b |
| KR102271574B1 (ko) | 2012-08-28 | 2021-07-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 |
| CA2881322A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| HK1215030A1 (zh) | 2012-11-09 | 2016-08-12 | Indiana University Research And Technology Corporation | 用於hbv組裝效應劑的替代用途 |
| WO2014089296A2 (en) | 2012-12-06 | 2014-06-12 | Institute For Hepatitis And Virus Research | Functionalized benzamide derivatives as antiviral agents against hbv infection |
| BR112015015584A2 (pt) | 2012-12-27 | 2017-12-12 | Baruch S Blumberg Inst | novos agentes antivirais contra infecção por hbv |
| WO2014131847A1 (en) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| MX353412B (es) | 2013-04-03 | 2018-01-10 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| BR112015028873A2 (pt) | 2013-05-17 | 2017-07-25 | Hoffmann La Roche | heteroaril-diidro-pirimidinas interligados na posição 6, para o tratamento e profilaxia de infecção pelo vírus da hepatite b |
| TWI733288B (zh) | 2013-05-17 | 2021-07-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| DK2997019T3 (en) | 2013-05-17 | 2018-12-03 | Janssen Sciences Ireland Uc | SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B |
| HRP20180791T1 (hr) | 2013-07-25 | 2018-09-07 | Janssen Sciences Ireland Uc | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b |
| WO2015073774A1 (en) * | 2013-11-14 | 2015-05-21 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis b infections |
| TW201620893A (zh) | 2014-02-06 | 2016-06-16 | 健生科學愛爾蘭無限公司 | 磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途 |
| JP2018510159A (ja) * | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゾカン及びアゾナン誘導体及びｂ型肝炎感染症の治療法 |
| CN105503730B (zh) * | 2015-12-25 | 2018-06-22 | 山东大学 | 吡唑类衍生物及其制备方法与应用 |
| UY37581A (es) * | 2017-02-02 | 2018-08-31 | Gilead Sciences Inc | Compuestos para el tratamiento de la infección por virus de la hepatitis b |
| CN108250112B (zh) * | 2018-01-30 | 2019-08-27 | 西北大学 | 一种1-烷基-1-芳硫基-2-(1h)-萘酮衍生物及其制备方法 |
-
2019
- 2019-10-22 CA CA3117449A patent/CA3117449A1/en active Pending
- 2019-10-22 SG SG11202104086PA patent/SG11202104086PA/en unknown
- 2019-10-22 KR KR1020217015135A patent/KR20210095143A/ko not_active Withdrawn
- 2019-10-22 EP EP19805797.8A patent/EP3870296A1/en not_active Withdrawn
- 2019-10-22 CN CN201980082985.8A patent/CN113195055A/zh active Pending
- 2019-10-22 MA MA053983A patent/MA53983A/fr unknown
- 2019-10-22 US US17/287,681 patent/US11560370B1/en active Active
- 2019-10-22 TW TW108138129A patent/TW202028190A/zh unknown
- 2019-10-22 JP JP2021547054A patent/JP2022508953A/ja active Pending
- 2019-10-22 AU AU2019364352A patent/AU2019364352A1/en not_active Abandoned
- 2019-10-22 WO PCT/US2019/057362 patent/WO2020086533A1/en not_active Ceased
- 2019-10-22 BR BR112021007602-6A patent/BR112021007602A2/pt not_active IP Right Cessation
- 2019-10-22 MX MX2021004580A patent/MX2021004580A/es unknown
-
2021
- 2021-04-19 IL IL282433A patent/IL282433A/en unknown
- 2021-04-21 PH PH12021550887A patent/PH12021550887A1/en unknown
-
2022
- 2022-11-17 US US17/989,237 patent/US12030869B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022508953A5 (enExample) | ||
| RU2007116119A (ru) | Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с | |
| JP2005532389A5 (enExample) | ||
| JP2017537949A5 (enExample) | ||
| JP2010504347A5 (enExample) | ||
| JP2010504346A5 (enExample) | ||
| JP2023502441A5 (enExample) | ||
| RU2011103741A (ru) | Композиции и способы лечения заболевания сетчатки | |
| JP2004516314A5 (enExample) | ||
| JP2008510771A5 (enExample) | ||
| RU2007123235A (ru) | Противоопухолевые соединения | |
| JP2008514732A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| JP2018021051A5 (enExample) | ||
| JP2009504763A5 (enExample) | ||
| JP2007511527A5 (enExample) | ||
| JP2012505836A5 (enExample) | ||
| JP2005538057A5 (enExample) | ||
| JP2014500265A5 (enExample) | ||
| JP2008503515A5 (enExample) | ||
| JP2003501474A5 (enExample) | ||
| RU2005107314A (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью | |
| JP2014531449A5 (enExample) | ||
| JP2011516610A5 (enExample) | ||
| JP2007529421A5 (enExample) |